Umbilical

NEXANS DELIVERS ROBUST PERFORMANCE IN 2023

Retrieved on: 
Thursday, February 15, 2024
Acquisition, Generation, Annual general meeting, ROCE, Aluminium, Engagement, Biophysical environment, Carbon accounting, Sale, Social responsibility, Climate, GHG, Umbilical, Policy, Science Based Targets initiative, Environment, Annual, Science, TriMet, Cryptocurrency

These two acquisitions add €500 million current sales in Electrification and enhance Nexans' global portfolio in key segments.

Key Points: 
  • These two acquisitions add €500 million current sales in Electrification and enhance Nexans' global portfolio in key segments.
  • Adjusted EBITDA reached €665 million in 2023, up by a strong +8.2% versus €616 million in 2022.
  • Adjusted EBITDA margin was strong at 10.2% versus 9.1% in 2022, supported by cable businesses and illustrating Nexans’ value-driven model and embedded focus on performance.
  • Notable developments in 2023 included:
    The accelerated deployment of the E3 performance model to ensure the convergence of Economic, Engagement and Environment pillars.

Cell BioEngines Licenses Patent for Allogeneic Hematopoietic Cell Transplantation in Oncology

Retrieved on: 
Thursday, September 7, 2023
Hematopoietic stem cell transplantation, HLA, Icahn School of Medicine at Mount Sinai, Intellectual property, CB, Culture, Hematology, Biotechnology, Clinical trial, Bone marrow, Pancreatic serous cystadenoma, MBA, Oncology, Doctor of Philosophy, HSCT, Health, Incidence, Patent, MD, Patient, Blood, Cell, Umbilical, HSC, B cell, Policy, FDA, Pharmaceutical industry, Vaccine

This technology has the potential to revolutionize the availability of universal donor cells derived from umbilical cord-blood and expand access to allogenic hematopoietic cell transplantation for patients, regardless of their geographical location or ethnic background.

Key Points: 
  • This technology has the potential to revolutionize the availability of universal donor cells derived from umbilical cord-blood and expand access to allogenic hematopoietic cell transplantation for patients, regardless of their geographical location or ethnic background.
  • Cell BioEngines, Inc. is a biotechnology company with the mission of revolutionizing cell therapies through the development of novel technologies and treatments.
  • Their latest innovation is a patent-licensed technology for allogeneic hematopoietic cell transplantation in blood and bone marrow cancer, which leverages small molecule-mediated expansion of engraftable cord-blood-derived HSCs to address donor availability for allo-HCT.
  • The large-scale generation of expanded cord-blood stem cells as an allogeneic donor source for adults with hematological malignancies is based on technology developed by Mount Sinai faculty and licensed to Cell BioEngines.

StemCyte Inc. Extends Umbilical Cord Blood Collection Operation at Three Hospital Collection Sites in Southern California

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Stem cells, Biology, Blood, Childbirth, Embryology, Cord blood bank, Sibling, Cord blood, Umbilical cord, Umbilical, Relicord

As these sites employ a hybrid collector-physician model, physicians and midwives will continue to collect cord blood afterhours.

Key Points: 
  • As these sites employ a hybrid collector-physician model, physicians and midwives will continue to collect cord blood afterhours.
  • This added coverage to each site allows StemCyte to be able to offer more patients the opportunity to participate in California\'s Umbilical Cord Blood Collection Program.\nThis Umbilical Cord Blood Collection Program (UCBCP) is aCalifornia statewide program administered by UC Davis Health.
  • "It is a great honor and privilege for StemCyte to be partnered with UC Davis for California\'s Umbilical Cord Blood Program (UCBCP).
  • The collection service is the state\'s first comprehensive public system for collecting cord blood that will be stored at an established, qualified cord blood bank like StemCyte.

StimLabs, LLC. Announces Launch of Second Umbilical Cord Derived Product: Corplex™ P

Retrieved on: 
Thursday, August 27, 2020
Branches of biology, Biology, Embryology, Stem cells, Developmental biology, Wharton's jelly, Umbilical cord, Connective tissue, Umbilical, Cryo-Save

Corplex P, a shelf-stable Wharton's Jelly allograft obtained from donated human umbilical cord tissue, is intended for homologous use for the supplementation of connective tissue voids in open wound environments.

Key Points: 
  • Corplex P, a shelf-stable Wharton's Jelly allograft obtained from donated human umbilical cord tissue, is intended for homologous use for the supplementation of connective tissue voids in open wound environments.
  • Corplex P was born out of a growing and widespread demand for a conformable placental derived product.
  • Corplex, StimLabs' first umbilical cord product was launched in early Q1, and Corplex P, an umbilical cord derivative, is available today.
  • Corplex P is a Wharton's Jelly allograft obtained from donated human umbilical cord tissue.

RF Technologies (RFT) COVID-19 Rapid Deployment Bundle Offerings - for Alternate Care Sites and Field Hospitals

Retrieved on: 
Monday, April 20, 2020
Infancy, Branches of biology, Childbirth, Cloning, Embryology, Umbilical cord, Umbilical, Infant, Biology

The COVID-19 SAFE PLACE Rapid Deployment Infant Security Bundle and CODE ALERT Rapid Deployment Nurse Call Bundle are an alternative wireless security and monitoring solution designed for quick deployment and self-installation.

Key Points: 
  • The COVID-19 SAFE PLACE Rapid Deployment Infant Security Bundle and CODE ALERT Rapid Deployment Nurse Call Bundle are an alternative wireless security and monitoring solution designed for quick deployment and self-installation.
  • The SAFE PLACE Rapid Deployment Infant Security Bundle is simple to use and designed for remote implementation to enable healthcare facilities to be fully operational on an accelerated schedule.
  • SAFE PLACE Rapid Deployment Infant Security Bundle components:
    Wireless Umbilical Tags The Umbilical Cord Transmitter is secured to the infant's umbilical cord clam and is worn on the umbilical stump.
  • The CODE ALERT Rapid Deployment Nurse Call Bundle is easy and automated providing nurse call assistance at the bedside using either pendants or call stations.

Regen Suppliers Now Offering 20% Discount On Biologics Orders to New Customers

Retrieved on: 
Friday, February 28, 2020
Life sciences, Biotechnology, Articles, Stem cells, Embryology, Regeneration, Umbilical cord, Umbilical, Biopharmaceutical, Regen

SCOTTSDALE, Ariz., Feb. 28, 2020 /PRNewswire-PRWeb/ -- Regen Suppliers is now offering first time customers a 20% discount on initial biologics orders.

Key Points: 
  • SCOTTSDALE, Ariz., Feb. 28, 2020 /PRNewswire-PRWeb/ -- Regen Suppliers is now offering first time customers a 20% discount on initial biologics orders.
  • Regen Suppliers offers an extensive variety of regenerative therapy products, including amniotic and umbilical tissue, Exosome Biologics, PRP kits, adipose kits, PDO thread lifts and more.
  • For example, Regen Suppliers has its own line for umbilical cord tissue and Exosome Biologics.
  • In addition, Regen Suppliers has also teamed up with R3 Medical Training for provider's regenerative medicine training courses .

Royal Biologics Announces the Launch of Cryo-Cord™, the First Non-DMSO Viable Umbilical Cord Graft

Retrieved on: 
Tuesday, January 21, 2020
Stem cells, Branches of biology, Embryology, Biology, Childbirth, Cloning, Umbilical cord, Umbilical

HACKENSACK, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Royal Biologics , an ortho-biologics company specializing in the research and advancement of novel ortho-biologics solutions, today announced the launch of Cryo-Cord, the first DMSO-free viable umbilical cord graft.

Key Points: 
  • HACKENSACK, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Royal Biologics , an ortho-biologics company specializing in the research and advancement of novel ortho-biologics solutions, today announced the launch of Cryo-Cord, the first DMSO-free viable umbilical cord graft.
  • These scientific presentations will feature several products within the Royal Biologics portfolio.
  • At its booth, Royal Biologics will showcase its comprehensive ALC portfolio designed to personalize live regenerative healing for a wide variety of wound types across the orthopedics continuum.
  • The launch of Cryo-Cord enables providers with the first DMSO-free viable umbilical cord tissue.

Port Townsend Family Receives $23.9 Million Verdict in Case against Jefferson Healthcare after Medical Errors Lead to Baby’s Permanent Brain Injury, According to Luvera Law Firm

Retrieved on: 
Monday, January 6, 2020
Professional services, Legal, Branches of biology, Childbirth, Cloning, Embryology, Umbilical cord, Jefferson Healthcare, Gellatly, Umbilical, Biology

A jurydecideda $23.9 million verdict in favor ofa Port Townsend family whose baby suffered permanent brain injury when she slowly suffocated during labor and delivery at Jefferson Healthcare Medical Center in 2014.

Key Points: 
  • A jurydecideda $23.9 million verdict in favor ofa Port Townsend family whose baby suffered permanent brain injury when she slowly suffocated during labor and delivery at Jefferson Healthcare Medical Center in 2014.
  • Lana was essentially strangled by her own umbilical cord and Jefferson Healthcare medical providers did nothing to intervene, said Robert Gellatly of Luvera Law Firm , the attorney representing Scott and Burke.
  • The medical teams actions or inactions deprived her of oxygen, leaving Lana profoundly brain injured."
  • Luvera Law Firm is a nationally recognized firm, with high standards of ethical conduct.

Insception Lifebank Recognizes World Cerebral Palsy Day

Retrieved on: 
Sunday, October 6, 2019
Branches of biology, Stem cells, Childbirth, Biology, Anatomy, Blood, Cord blood, Cerebral palsy, Umbilical cord, Umbilical, World Cerebral Palsy Day

TORONTO, Oct. 6, 2019 /CNW/ - To mark World Cerebral Palsy Day on October 6th, Insception Lifebank is sharing a family story that shines a light on the potential impact umbilical cord blood stem cells may have in treating this debilitating condition.

Key Points: 
  • TORONTO, Oct. 6, 2019 /CNW/ - To mark World Cerebral Palsy Day on October 6th, Insception Lifebank is sharing a family story that shines a light on the potential impact umbilical cord blood stem cells may have in treating this debilitating condition.
  • Nosheen and Abdul stored Anaya's umbilical cord blood via Insception Lifebank's free Cerebral Palsy Sibling Collection Program.
  • For more information about storing umbilical cord blood or the Cerebral Palsy Sibling Collection Program, please contact Insception Lifebank at 1-866-606-2790 or visit www.insception.com .
  • iDuke University Medical Center Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries https://clinicaltrials.gov/ct2/show/NCT03327467 Accessed on October 4, 2019.
    ii Ontario Federation for Cerebral Palsy A Guide to Cerebral Palsy.

Umbilical Cord Blood Banking Market to Expand at a Strong 11.4% CAGR, Vast Applications in Cell-based Therapies to Boost Rapid Expansion - TMR

Retrieved on: 
Tuesday, August 27, 2019
Stem cells, Branches of biology, Biology, Childbirth, Blood, Life sciences, Embryology, Cloning, Umbilical cord, Cord blood, Umbilical

Moreover, the growth of the market is also expected to ride on the vast application of umbilical cord blood in various cell-based therapies.

Key Points: 
  • Moreover, the growth of the market is also expected to ride on the vast application of umbilical cord blood in various cell-based therapies.
  • According to the analysis by the experts at Transparency Market Research, the global umbilical cord blood banking market is expected to offer various growth opportunities to the players.
  • Owing to the evident humungous growth potential, the global umbilical cord blood banking market is expected to expand at a strong 11.4% CAGR during the forecast period.
  • On the basis of storage type, the global umbilical cord blood banking market is bifurcated into two segments, namely, public and private banks.